# Abraxane and Temodar Plus Genasense in Advanced Melanoma

> **NCT00409383** · PHASE1 · UNKNOWN · sponsor: **Genta Incorporated** · enrollment: 28 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Genasense® (oblimersen)
- **DRUG:** Abraxane® (paclitaxel protein-bound particles for injectable suspension)
- **DRUG:** Temodar® (temozolomide)

## Key facts

- **NCT ID:** NCT00409383
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-11
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2011-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00409383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00409383, "Abraxane and Temodar Plus Genasense in Advanced Melanoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00409383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*